{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-029869","form_type":"8-K/A","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.018592+00:00","generated_at":"2026-06-14T01:18:46.414544+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AVROBIO amends 8-K: no material charges from cystinosis gene therapy asset sale","bullets":["Amendment to prior 8-K (May 22, 2023) regarding sale of cystinosis gene therapy program.","Company had previously been unable to estimate related charges; now determines no material charges expected.","Asset sale includes all assets specifically related to the cystinosis gene therapy program.","No change to other disclosures in the original Form 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-029869","json":"https://secwatch.observer/filing/0001140361-23-029869.json","markdown":"https://secwatch.observer/filing/0001140361-23-029869.md","text":"https://secwatch.observer/filing/0001140361-23-029869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123029869/0001140361-23-029869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123029869/brhc20054447_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:18:46.414544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}